New cocktail aims to shrink Hard-to-Treat colon tumors
NCT ID NCT05999812
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This phase 2 trial is testing a combination of three drugs—ATRA (a vitamin A derivative), bevacizumab (a blood vessel growth blocker), and atezolizumab (an immunotherapy)—in 22 people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this mix can shrink tumors or stop them from growing. Participants receive ATRA pills at home and the other two drugs through an IV every two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
all-trans-retinoic acid (ATRA), bevacizumab, and atezolizumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply to a larger population. The combination may cause significant side effects, and the cancer may still progress.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.